Béla Flerkó

Gonadotropin-releasing hormone (GnRH) neurons and pathways in the rat brain

SummaryGonadotropin-releasing hormone (GnRH) neurons and their pathways in the rat brain were localized by immunocytochemistry in 6-to 18-day-old female animals, by use of thick frozen or vibratome sections, and silver-gold intensification of the diaminobenzidine reaction product. GnRH-immunoreactive perikarya were observed in the following regions: olfactory bulb and tubercle, vertical and horizontal limbs of the diagonal band of Broca, medial septum, medial preoptic and suprachiasmatic areas, anterior and lateral hypothalamus, and different regions of the hippocampus (indusium griseum, Ammons horn). In addition to the known GnRH-pathways (preoptico-terminal, preoptico-infundibular, periventricular), we also observed GnRH-immunopositive processes in several major tracts and areas of the brain, including the medial and cortical amygdaloid complex, stria terminalis, stria medullaris thalami, fasciculus retroflexus, medial forebrain bundle, indusium griseum, stria longitudinalis medialis and lateralis, hippocampus, periaqueductal gray of the mesencephalon, and extracerebral regions, such as the lamina cribrosa, nervus terminalis and its associated ganglia. By use of the silver-gold intensification method we present Golgi-like images of GnRH perikarya and their pathways. The possible distribution of efferents from each GnRH cell group is discussed.

Ultrastructural characteristics of immunolabelled, corticotropin releasing factor (CRF)-synthesizing neurons in the rat brain

SummaryThe corticotropin releasing factor (CRF)-synthesizing perikarya and neural processes were detected at ultrastructural level in the hypothalamic paraventricular nucleus and in the median eminence of control and colchicine-pretreated rats. The unlabelled antibody peroxidase-antiperoxidase complex (PAP) immunohistochemical method was used in a pre-embedding manner, on thick, non-frozen sections. In CRF-perikarya, neurosecretory granules (80–120 nm in diameter), free ribosomes, and the rough endoplasmic reticulum were labelled. Unlabelled axon terminals formed asymmetric synapses on CRF-containing perikarya and dendrites. Immunolabelled axons terminated in the palisadic zone of the median eminence.

Immunohistological detection of degenerating CRF-immunoreactive nerve fibers in the median eminence after lesion of paraventricular nucleus of the rat. A light and electron microscopic study

Corticotropin releasing factor (CRF)-immunoreactive neurons were detected in the paraventricular nuclei (PVN) of the rat brain, using both the traditional and the recently developed silver-gold intensified PAP methods at light and electron microscopic levels. The latter technique was more sensitive, compared to the classical PAP method, and proved to be highly specific at the ultrastructural level. The immunolabeled perikarya showed smooth or rough contoured fusiform or multipolar shape. Bilateral surgical destruction of PVN caused a gradual decrease in the number of CRF-immunopositive fibers of the median eminence. Following the second post-operative week, CRF-immunoreactivity practically disappeared from this area. In the case of unilateral lesion of PVN, the diminution of immunoreactivity was restricted to the ipsilateral side of the median eminence-pituitary stalk region. Applying the silver-gold intensified PAP method to electron microscopy, the detection of immuno-labeled degenerating fibers became possible, among morphologically similar, densely degenerating, but unlabeled, profiles. This study reports that CRF fibers to the capillary system of the median eminence of the rat originate principally from PVN.

Lamprey Gonadotropin Hormone-Releasing Hormone-III has No Selective Follicle-Stimulating Hormone-Releasing Effect In Rats

Lamprey gonadotropin releasing‐hormone (LGnRH)‐III, a hypothalamic neurohormone recently isolated from sea lamprey, was reported to have a selective stimulatory effect on follicle‐stimulating hormone (FSH) release in rats and suggested to be the mammalian FSH‐releasing factor. In this study, we determined the relative luteinizing hormone (LH)‐ and FSH‐releasing potency of LGnRH‐III compared to mammalian gonadotropin‐releasing hormone (LHRH) in normal female rats, ovariectomized (OVX) and oestrogen/progesterone substituted rats and the superfused rat‐pituitary cell system. The specificity of LGnRH‐III for the mammalian LHRH receptor was investigated by blocking the receptor with an LHRH antagonist, MI‐1544. In vitro, LGnRH‐III dose‐dependently stimulated both LH and FSH secretion from rat pituitary cells at 10−7 to 10−5 M concentrations, while LHRH stimulated gonadotropin secretion at a 1000‐fold lower doses (10−10 to 10−8 M). The difference between its LH‐ and FSH‐releasing potency was similar to that of LHRH. LGnRH‐III bound to high affinity binding sites on rat pituitary cells with a Kd of 6.7 nm, Bmax=113±27 fmol/mg protein. In vivo, LGnRH‐III also stimulated both LH and FSH secretion in a dose‐dependent manner and, similar to LHRH, induced a greater rise in the serum LH than the FSH level. In normal cycling rats, it showed 180–650‐fold weaker potency than LHRH in stimulating LH secretion and 70–80‐fold weaker effect in stimulating FSH secretion. In OVX rats, LGnRH‐III demonstrated a similarly weak effect on both gonadotropins. It was found to be 40–210‐fold less potent than LHRH regarding LH release and 50–160‐fold weaker regarding FSH release. LHRH‐receptor antagonist MI‐1544 prevented both the LH‐ and the FSH‐releasing effect of LGnRH‐III both in vitro and in vivo. These results do not support the hypothesis that LGnRH‐III might be the mammalian FSH‐releasing factor but demonstrate that it is a weak agonist for the pituitary LHRH receptor and stimulates both gonadotropins in a dose‐dependent fashion.

Immunocytochemical localization of the gonadotropin-releasing hormone-associated peptide portion of the LHRH precursor in the hypothalamus and extrahypothalamic regions of the rat central nervous system

SummaryThe gonadotropin-releasing hormone-associated peptide (GAP) of the LHRH precursor and the decapeptide LHRH were localized in the rat brain by immunocytochemistry in 12 to 18-day-old animals, by use of thick Vibratome sections and nickel intensification of the diaminobenzidinereaction product. Our results indicate that the GAP portion of the LHRH precursor is present in the same population of neurons that contain LHRH in the rat brain. An important difference observed was that the GAP antiserum, in contrast to LHRH antisera, stained several perikarya in the medial basal hypothalamus. GAP-immunoreactive perikarya were observed in the following regions: the olfactory bulb and tubercle, diagonal band of Broca, medial septum, medial preoptic and suprachiasmatic areas, anterior and lateral hypothalamus, and several regions of the hippocampus. In addition to the preoptico-terminal and the septopreoptico-infundibular pathways, we also observed GAPimmunopositive processes in several major tracts and areas of the brain, including the amygdala, stria terminalis, stria medullaris thalami, fasciculus retroflexus, stria longitudinalis medialis, periventricular plexus, periaqueductal gray of the mesencephalon and extra-cerebral regions, such as the nervus terminalis and its associated ganglion. These results confirm the specificity of previous immunocytochemical results obtained with antisera to LHRH. The presence of GAP immunoreactivity in nerve terminals of the rat brain indicates that GAP or a GAP-like peptide is located in the proper site to serve as a hypophysiotropic substance and/or as a neurotransmitter or neuromodulator.

Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system

A powerful GnRH antagonist: [Ac-D-Trp1,3,D-Cpa2,D-Lys6,D-Ala10]-GnRH (MI-1544) and a superactive GnRH agonist: [D-Phe6,desGly10]-GnRH(1-9)EA (OVURELIN) were used in long-term administration to compare their effects on the inhibition of ovulation, LH and progesterone (P) release, LH content of pituitaries as well as on the recovery period. Both analogs showed 100% inhibitory effects on ovulation in very low doses during the daily treatment for 21 days. The antagonist prevented LH release already after the first injection, decreased the serum P level to 40%, and increased the LH content of the pituitary up to 180%, inhibiting only the release but not the synthesis of LH. The agonist showed marked LH-releasing effects on the first day of the treatment, which were reduced to 12% on the 7th day. Serum P concentration was dropped to 68% by the end of the treatment. No change was found in the LH content of pituitaries in the group treated with the agonist. Ovaries showed polifollicular pictures in the antagonist-treated group, and persistent corpora lutea were seen in the ovaries from the agonist-treated group. Regular estrous cycles returned 13-15 days after ceasing the treatment with the antagonist and 3-5 days after ceasing the treatment with the agonist. No edema-inducing effect was observed after the injections of the antagonist in doses of 100 times higher than the single antiovulatory dose.

The origin and ultrastructural characteristics of corticotropin-releasing factor (CRF)-immunoreactive nerve fibers in the posterior pituitary of the rat

SummaryA fine network of corticotropin-releasing factor (CRF)-immunopositive fibers was found in the posterior lobe of the pituitary of the rat. The intermediate and distal lobes were free of CRF-immunoreactivity. Varicose, terminal-like axons were frequently observed around capillary vessels. Surgical isolation of the paraventricular nuclei resulted in a complete disappearance of CRF-immunoreactive fibers from the posterior lobe. CRF-immunopositive fibers show the general characteristics of peptidergic axons. These ultrastructural observations support the idea that CRF is secreted into capillary vessels.

Long-term inhibition of ovulation by a GnRH-antagonist at low dose level

Ac-D-Trp1,3, D-Cpa2, D-Lys6, D-Ala10-GnRH has been prepared by solid phase synthesis. The peptide was found to completely inhibit ovulation when administered on proestrus day in a dose of 1.5 microgram/rat, s.c. The peptide completely inhibited ovulation for a period corresponding to three to four cycles when administered daily in a dose of 5 micrograms/rat, s.c. and caused 70% inhibition of ovulation in a dose of 3 micrograms/rat.

Antiovulatory doses of antagonists of LH-RH inhibit LH and progesterone but not FSH and estradiol release

The differential regulation of immunoactive FSH and LH secretion by endogenous LH‐RH was studied using LH‐RH antagonists (Ac‐D‐Trp1,2, D‐Cpa2, D‐Lys6, D‐Ala10LH‐RH (MI‐1544) and (Ac‐D‐Nal1, D‐Phe(pCI2), D‐Trp3, D‐Cit6, D‐Ala10LH‐RH (SB‐030) in ovariecto‐mized (OVX) and regularly cycling rats. Single injections of 10 μg and 100 μg doses and long‐term treatment with 10 μg doses of MI‐1544 were used in OVX animals. Serum and pituitary LH and FSH, as well as serum estradiol and progesterone was determined by RIA during and/or after the treatment. Single injections of MI‐1544 in OVX animals caused prompt (in 2 h) and long‐lasting (for more than 24 h) suppression of the serum LH, while no or late decrease (after more than 6 h) of the serum FSH. Long‐term treatment with the same analog decreased the serum LH (by 50%) and moderately increased the pituitary LH (by 21%) but did not change the serum and the pituitary FSH concentrations. In normal rats, long‐term treatment with both of our analogs also resulted in divergent alterations in the LH and FSH concentrations. Serum LH dropped to undetectable levels, while serum FSH did not change significantly. Pituitary LH increased (by 31 to 41%), while FSH decreased (by 27 to 38%). Marked depression was found in the serum progesterone (by 64%) but no significant change in the serum estradiol levels, after the long‐term treatment for 21 days. The ovarian cycles were interrupted, and no ovulation appeared during the treatment. Significant decrease was detectable in the weight of the ovaries (by 46%), whereas the weight of the uteri did not change or slightly elevated (by 22%), after the treatment with SB‐030 or MI‐1544, respectively. The clear antagonistic effect of the analogs on the LH‐RH‐stimulated LH and FSH release was tested in the in vitro superfused rat pituitary cell system. In this system our analogs provented both the LH‐and the FSH‐releasing effect of the LH‐RH. The inhibitory effect was longer‐lasting on the FSH than on the LH release. Our studies give evidences that the long‐term treatment with antiovulatory doses of LH‐RH antagonists suppress the LH and progesterone but not the FSH and estradiol secretion and indirectly support the earlier publications suggesting the presence of FSH‐releasing factor(s) in the CNS.

Effects of continuous and repetitive administration of a potent analog of GH-RH(1-30)NH2 on the GH release in rats

We examined the desensitization and/or sensitization phenomenon in the pituitary GH responsiveness induced by continuous infusion and multiple pulses at different frequencies of a potent GH-RH analog [D-Ala2, Leu15, Nle27, GABA30-GH-RH(1-30)amide]. Further, we investigated the correlation between doses and GH responses, as well as between pulse frequency and GH responses in male rats in vivo and in vitro. Long-term, continuous administration was attained by osmotic minipumps releasing low and high doses of the analog for 14 days. The effects of repetitive administration of the GH-RH analog on the pituitary GH release was investigated by injecting 4-6 pulses of the analog at different doses and pulse frequencies. The in vitro experiments were performed in the superfused rat anterior pituitary cell system. Pituitary cells were challenged with continuous, repetitive and simultaneous continuous and repetitive perfusion of the analog. Continuous infusion with low doses of the GH-RH analog in vivo induced sensitization of the pituitary GH-secretory responsiveness and resulted in moderately increased GH releases (129% of the control) to additional bolus injections of the same analog, whereas continuous stimulation of the pituitary with high doses of the GH-RH analog evoked desensitization and resulted in blunted GH responses (29% of the control). Despite the desensitization of the pituitary GH-secretory responsiveness, high doses of the analog elevated the serum GH concentration to 310% and induced acceleration of body weight gain (160% of the control). Repetitive pulsatile administration of the GH-RH analog evoked both sensitization and desensitization of the pituitary GH-secretory responsiveness, depending on the dose and pulse frequency administered.(ABSTRACT TRUNCATED AT 250 WORDS)